In this study, we addressed the question whether the dose of Melan-A peptide and of CpG-B adjuvant used for therapeutic vaccination of melanoma patients can influence the in vivo expansion, differentiation, avidity, and function of the responding CD8 T-cells. The gene discussed is CD8A; the disease is melanoma.